NEUROENDOCRINE TUMORS

This study tested a treatment called TheraSphere, which delivers tiny radioactive beads directly to liver tumors through the blood vessels. It included 24 adults with neuroendocrine tumors that had spread to the liver and could not be removed by surgery. The goal was to see if th…

This early-phase study tested a combination of two drugs (177Lu-DOTA-TATE and olaparib) in 18 people with certain types of tumors that have a specific marker (somatostatin receptors). The goal was to see if the combination is safe and to measure how well it works. The approach ai…

This study tested a drug called surufatinib in 36 Japanese patients with neuroendocrine tumors that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors and control the disease. The study was completed and measured side effects and ho…

This study tested a new oral drug (BXCL701) combined with an immunotherapy (pembrolizumab) in 98 men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to find the right dose and see if the combo can shrink tumors or slow the disease. Participa…

This study tested whether adding the oral drug axitinib to standard sandostatin therapy could slow cancer growth in 256 people with advanced neuroendocrine tumors (non-pancreatic). Participants had tumors that were growing despite prior treatment. The main goal was to see how lon…

This study tested a combination of two drugs, pembrolizumab and lenvatinib, in 20 adults with advanced neuroendocrine tumors that had worsened despite prior treatments. The goal was to see if the combination could shrink tumors or slow cancer growth. Participants received the dru…

This study followed 20 people with neuroendocrine tumors who had already received the experimental drug 177Lu-IPN01072 in an earlier trial. The goal was to check for long-term side effects, such as new cancers. No new treatment was given; participants were simply monitored over t…

This study looked at 116 people with advanced neuroendocrine tumors (NETs) to see if a marker called MGMT can predict which chemotherapy works best. Researchers compared two chemo types—alkylating agents and oxaliplatin—based on the tumor's MGMT status. The goal is to personalize…

This study looked at medical records of 168 people with a rare type of digestive neuroendocrine tumor. The goal was to see if one chemotherapy approach works better than another. Researchers hope the findings will help doctors choose the best treatment for these uncommon tumors.

This study looked at how often the EchoTip AcuCore biopsy needle successfully gets a tissue sample during endoscopic ultrasound procedures. It included 183 adults with various conditions like cancer or pancreatitis. The goal was to gather real-world information on the device's pe…